dr. max dean cancer researcher at stanford. pathway cites his research as evidence their test can detect cancer in otherwise healthy patients. >> i think we are still years away from that possibility. >> reporter: years? >> years. that absolutely requires thousands of patients and long term trials to prove that. >> reporter: thousands of patients. years of testing. millions of dollars. >> correct. doing any of the three. >> i zoent think i would order that test. >> pathway has three clinical trials under way to study its liquid by on tee. but they all started months after the test was put on the market. following our interview, pathway removed the marketing video from its website telling us they "had proactively decided to limit some of our marketing activities intercement." in september, fda sent pathway genomics a lettera citing concerns the test did not have adequate clinical validation and may harm the public health. >>> we'll heavy part two of jim's investigation tomorrow. check this out, bro. what's that, broheim? i switc

dr. max dean cancer researcher at stanford. pathway cites his research as evidence their test can detect cancer in otherwise healthy patients. away from that possibility. >> reporter: years? >> years. that absolutely requires thousands of patients and long term trials to prove that. >> reporter: thousands of years of testing. millions of dollars. >> correct. >> reporter: if a company isn't doing any of the three. >> i've don't think i would order the test. >> the food and drug administration tells us it considers tests like cancer intercept a health risk. they sent ape letter citing concerns the test did not have adequate clinical validation and may harm the public. after our interview, pathway did pull that promotional data from its website. >> jim, thank you very much. great report. you are probably wondering how the companies are able to sell unproven tests. jim will have more on that on "cbs this morning." >>> federal health officials sent hundreds of kits to florida to test for the zika virus. 16 cases are confirmed there.

dr. max dean cancer researcher at stanford. pathway cites his research as evidence their test can detect cancer in otherwise healthy patients. >> i think we are still years away from that possibility. >> reporter: years? >> years. that absolutely requires thousands of patients and long term trials to prove that. >> reporter: thousands of patients. millions of dollars. >> correct. >> reporter: if a company isn't doing any of the three. >> i've don't think i would order the test. >> the food and drug administration tells us it considers tests like cancer intercept a health risk. they sent ape letter citing concerns the test did not have adequate clinical validation and may harm the public. and pathway has tests under way. after our interview, pathway did pull that promotional data from its website. >> jim, thank you very much. great report. you are probably wondering how the companies are able to sell unproven tests. jim will have more on that on "cbs this morning." >>> federal health officials sent hundreds of kits to florida to

dr. max dean is a pathway cites his research as evidence their test can detect cancer in otherwise healthy patients. >> i think we're still years away from that possibility. while we have -- >> reporter: years. >> years. that absolutely requires thousands of patients and long-term trials to prove that. >> reporter: thousands of patients, years of testing, millions of dollars. >> correct. >> reporter: and if a company isn't doing any of those three? >> then i don't think i would order that test. >> reporter: the food and drug administration tells us can considers tests like cancer intercept a major health risk. in september, the f.d.a. sent pathway genomics a letter citing concerns the test did not have adequate clinical validation and may harm the public health. pathway now has three clinical trials under way to study its liquid biopsy, but it all began after the test was already on the market. and, scott, after our interview, pathway did pull that >> pelley: jim, thanks very much. great report. you're probably wondering how these companies are able to sell unproven tests. well, jim will h

dr. max dean cancer researcher at stanford. pathway cites his research as evidence their test can detect caer in otherwise healaly patients. >> i think we are still years away from that possibility. >> reporter: years? >> years. that absolutely requires thousands of patients and long term trials to prove that. >> reporter: thousands of millions of dollars. >> correct. >> reporter: if a company isn't doing any of the three. >> i've don't think i would order the test. >> the food and drug administration tells us it considers tests like cancer intercept a health risk. they sent ape letter citing concerns the test did not have adequate clinical validation and may harm the public. and pathway has tests under way. after our interview, pathway did pull that promotional data from its website. >> jim, thank you very much. great report. you are probably wondering how the companies are able to sell unproven tests. jim will have more on that on "cbs this morning." >>> federal health officials sent hundreds of kits to florida to test for th

dr. max dean is a cancer researcher at stanford. pathway cites his research as evidence their test can detect cancer in otherwise healthy patients. >> i think we're still years away from that possibility. while we have -- >> reporter: years? >> years. that absolutely requires thousands of patients and long- term trials to prove that. >> reporter: thousands of patients, years of testing, millions of dollars. >> correct. isn't doing any of those three? >> then i don't think i would order that test. ep >> reporter: the food and drug administration tells us it considers tests like cancer intercept a major health risk. in september, the f.d.a. sent pathway genomics a letter citing concerns the test did not have adequate clinical validation and may harm the public health. pathway now has three clinical trials under way to study its liquid biopsy, but it all began after the test was already on the market. and, scott, after our interview, pathway did pull that promotional data from its web site. >> pelley: jim, thanks very much. y great rep